Acura Pharma Cmn (ACUR) 1.91 $ACUR
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), NVLS: 4.76 (+0.08), CYTR: 0.60 (-0.05), CEMP: 18.50 (+0.53), ACUR: 1.91 (-0.03), NVS: 83.07 (-0.19)
Acura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities
Marketwire Canada - Wed Jun 08, 3:15PM CDT
Topline Results From Study AP-LTX-400 Cohort 2
ACUR: 1.91 (-0.03)
Egalet Settles Patent Litigations with Purdue Pharma
PR Newswire - Mon May 23, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII. In April 2015 and April 2016 Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. filed patent infringement lawsuits against Egalet for OXAYDO alleging the product infringes Purdue's U.S. Patent No. 8,389,007 and U.S. Patent No. 9,308,171, respectively. Purdue has agreed to dismiss the complaints and both parties have agreed not to pursue any further action on OXAYDO, an immediate-release opioid product. There are no financial obligations to either party.
EGLT: 7.02 (-0.37), ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Marketwired - Mon May 02, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016.
EGLT: 7.02 (-0.37), ACUR: 1.91 (-0.03)
Indiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem
Marketwired - Thu Apr 28, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced that, today, Indiana Governor Mike Pence will formally sign legislation designed to address and slow the "home-grown" meth problem in Indiana. The new law, known as Senate Enrolled Act 80, requires state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. The law requires rule and policy making by the Indiana Board of Pharmacy, including the determination of products that are meth-resistant. Upon enactment, pharmacists who do not have a relationship with a customer may, at their discretion after consultation with the customer, sell only a methamphetamine-resistant pseudoephedrine product such as Nexafed®, or a minimal supply of a traditional pseudoephedrine product. The new bill will go into effect on July 1, 2016 and will be signed at Webb's Family Pharmacy in Rochester, Ind.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology
Marketwired - Tue Apr 26, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 9,320,796 by the United States Patent and Trademark Office pertaining to the Company's Limitx(TM) Technology platform.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016
Marketwired - Thu Apr 21, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the first quarter 2016 following the close of financial markets on Monday, May 2, 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016 at 8:30 a.m. ET.
ACUR: 1.91 (-0.03)
Acura Pharmaceutical's Limitx(TM) Technology Successfully Demonstrates Oral Abuse Deterrence
Marketwired - Wed Apr 13, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline interim results from clinical study AP-LTX-400 demonstrated one test formulation of LTX-04, a hydromorphone hydrochloride immediate-release tablet using the Company's new LIMITX oral abuse deterrent technology, successfully demonstrated the release of the active opioid ingredient was reduced when three intact tablets were ingested but that additional formulation development will be required for LTX-04 to deliver a sufficient amount of the active ingredient to patients when one or two tablets are administered. Study AP-LTX-400 is a two cohort pharmacokinetic study with today's results limited to the first of the two cohorts. The second cohort of the study is expected to commence later this month.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04
Marketwired - Tue Apr 12, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of LTX-04, Acura's hydromorphone HCl tablets utilizing its oral abuse deterrent LIMITX technology, for the management of pain in patients where an opioid analgesic is appropriate.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective
Marketwired - Wed Mar 30, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that its universal shelf registration statement on Form S-3, as amended, was declared effective by the Securities and Exchange Commission (SEC) today.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Acknowledges Inclusion of Meth-Resistant Technology in Indiana Legislation
Marketwired - Mon Mar 14, 3:10PM CDT
On Thursday, March 10, 2016 the Indiana General Assembly passed legislation to require state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. The Indiana bill has been sent to Indiana Governor Mike Pence for his signature and will require rule and policy making by the Indiana Board of Pharmacy, including the determination of products that are meth-resistant. If the bill is enacted, pharmacists who do not have a relationship with a customer may, at their discretion after consultation with the customer, sell only a methamphetamine resistant pseudoephedrine product such as Nexafed®, or a minimal supply of a traditional pseudoephedrine product.
ACUR: 1.91 (-0.03)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), NVLS: 4.76 (+0.08), CYTR: 0.60 (-0.05), CEMP: 18.50 (+0.53), ACUR: 1.91 (-0.03), NVS: 83.07 (-0.19)
Acura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities
Marketwire Canada - Wed Jun 08, 3:15PM CDT
Topline Results From Study AP-LTX-400 Cohort 2
ACUR: 1.91 (-0.03)
Egalet Settles Patent Litigations with Purdue Pharma
PR Newswire - Mon May 23, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII. In April 2015 and April 2016 Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. filed patent infringement lawsuits against Egalet for OXAYDO alleging the product infringes Purdue's U.S. Patent No. 8,389,007 and U.S. Patent No. 9,308,171, respectively. Purdue has agreed to dismiss the complaints and both parties have agreed not to pursue any further action on OXAYDO, an immediate-release opioid product. There are no financial obligations to either party. EGLT: 7.02 (-0.37), ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Marketwired - Mon May 02, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016.
EGLT: 7.02 (-0.37), ACUR: 1.91 (-0.03)
Indiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem
Marketwired - Thu Apr 28, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced that, today, Indiana Governor Mike Pence will formally sign legislation designed to address and slow the "home-grown" meth problem in Indiana. The new law, known as Senate Enrolled Act 80, requires state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. The law requires rule and policy making by the Indiana Board of Pharmacy, including the determination of products that are meth-resistant. Upon enactment, pharmacists who do not have a relationship with a customer may, at their discretion after consultation with the customer, sell only a methamphetamine-resistant pseudoephedrine product such as Nexafed®, or a minimal supply of a traditional pseudoephedrine product. The new bill will go into effect on July 1, 2016 and will be signed at Webb's Family Pharmacy in Rochester, Ind.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology
Marketwired - Tue Apr 26, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 9,320,796 by the United States Patent and Trademark Office pertaining to the Company's Limitx(TM) Technology platform.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016
Marketwired - Thu Apr 21, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the first quarter 2016 following the close of financial markets on Monday, May 2, 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016 at 8:30 a.m. ET.
ACUR: 1.91 (-0.03)
Acura Pharmaceutical's Limitx(TM) Technology Successfully Demonstrates Oral Abuse Deterrence
Marketwired - Wed Apr 13, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline interim results from clinical study AP-LTX-400 demonstrated one test formulation of LTX-04, a hydromorphone hydrochloride immediate-release tablet using the Company's new LIMITX oral abuse deterrent technology, successfully demonstrated the release of the active opioid ingredient was reduced when three intact tablets were ingested but that additional formulation development will be required for LTX-04 to deliver a sufficient amount of the active ingredient to patients when one or two tablets are administered. Study AP-LTX-400 is a two cohort pharmacokinetic study with today's results limited to the first of the two cohorts. The second cohort of the study is expected to commence later this month.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04
Marketwired - Tue Apr 12, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of LTX-04, Acura's hydromorphone HCl tablets utilizing its oral abuse deterrent LIMITX technology, for the management of pain in patients where an opioid analgesic is appropriate.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective
Marketwired - Wed Mar 30, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that its universal shelf registration statement on Form S-3, as amended, was declared effective by the Securities and Exchange Commission (SEC) today.
ACUR: 1.91 (-0.03)
Acura Pharmaceuticals Acknowledges Inclusion of Meth-Resistant Technology in Indiana Legislation
Marketwired - Mon Mar 14, 3:10PM CDT
On Thursday, March 10, 2016 the Indiana General Assembly passed legislation to require state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. The Indiana bill has been sent to Indiana Governor Mike Pence for his signature and will require rule and policy making by the Indiana Board of Pharmacy, including the determination of products that are meth-resistant. If the bill is enacted, pharmacists who do not have a relationship with a customer may, at their discretion after consultation with the customer, sell only a methamphetamine resistant pseudoephedrine product such as Nexafed®, or a minimal supply of a traditional pseudoephedrine product.
ACUR: 1.91 (-0.03)
